ANTAGONISM OF ACUTE COCAINE TOXICITY BY BUPRENORPHINE

被引:19
作者
SHUKLA, VK
GOLDFRANK, LR
TURNDORF, H
BANSINATH, M
机构
[1] NYU MED CTR,DEPT ANESTHESIOL,550 1ST AVE,NEW YORK,NY 10016
[2] NYU MED CTR,DEPT EMERGENCY MED SERV,NEW YORK,NY 10016
关键词
D O I
10.1016/0024-3205(91)90289-N
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The effect of buprenorphine pretreatment on the acute cocaine toxicity was assessed in male Swiss Webster mice. Buprenorphine pretreatment (0.15 or 0.30 mg/kg ip, 30 mins before) significantly attenuated the lethal effects of cocaine (60-140 mg/kg ip). The dose of cocaine which resulted in 50% mortality (LD50) in saline pretreated group was 100.61 mg/kg while the LD50 of cocaine in buprenorphine (0.15 and 0.3 mg/kg) pretreated groups were 113.57 and 118.16 mg/kg respectively. There was no significant change in the ratio of brain/plasma levels of cocaine in buprenorphine pretreated group when compared to the ratio from saline treated controls. Furthermore, neither naloxone (10 mg/kg ip, 15 mins before) nor naltrexone (3 mg/kg ip, 15 mins before) pretreatment affected the LD50 of cocaine. When tested 0.5, 1, 2, 4, 8 and 24 hrs after cocaine administration, sublethal dose of cocaine (80 mg/kg ip) injection resulted in significant increase in the plasma lactate dehydrogenase (LDH) levels. Buprenorphine pretreatment significantly attenuated cocaine-induced release of LDH. These results suggest that buprenorphine could be of potential advantage over naloxone in the management of cocaine and heroin ("speed ball") toxicity and in studies on the pharmacotherapy of cocaine-induced toxicity, LDH levels may be used as a biochemical marker to assess the protective effects of drugs.
引用
收藏
页码:1887 / 1893
页数:7
相关论文
共 20 条
[1]  
BANSINATH M, 1991, FASEB J, V5, pA1563
[2]  
BROWN EE, 1991, J PHARMACOL EXP THER, V256, P119
[3]  
CLOUET D, 1988, NATL I DRUG ABUSE RE, V88, pR9
[4]   COCAINE - CLINICAL-PHARMACOLOGY AND TOXICOLOGY [J].
FARRAR, HC ;
KEARNS, GL .
JOURNAL OF PEDIATRICS, 1989, 115 (05) :665-675
[5]   USE OF BUPRENORPHINE IN THE TREATMENT OF OPIOID ADDICTION .2. PHYSIOLOGIC AND BEHAVIORAL-EFFECTS OF DAILY AND ALTERNATE-DAY ADMINISTRATION AND ABRUPT WITHDRAWAL [J].
FUDALA, PJ ;
JAFFE, JH ;
DAX, EM ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (04) :525-534
[6]   COCAINE ADDICTION - PSYCHOLOGY AND NEUROPHYSIOLOGY [J].
GAWIN, FH .
SCIENCE, 1991, 251 (5001) :1580-1586
[7]   THE CARDIOVASCULAR EFFECTS OF COCAINE [J].
GOLDFRANK, LR ;
HOFFMAN, RS .
ANNALS OF EMERGENCY MEDICINE, 1991, 20 (02) :165-175
[8]   BUPRENORPHINE - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY [J].
HEEL, RC ;
BROGDEN, RN ;
SPEIGHT, TM ;
AVERY, GS .
DRUGS, 1979, 17 (02) :81-110
[9]  
HIGGINS ST, 1990, AM J MED, V89, P544, DOI 10.1016/0002-9343(90)90397-V
[10]  
KAMIEN J B, 1990, FASEB Journal, V4, pA593